IQVIA (NYSE:IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company helps organizations develop and commercialize therapies by combining data science, real-world evidence and domain expertise. IQVIA’s offerings span the entire product lifecycle, from early-stage clinical development through post-market safety monitoring and commercial optimization.
The company’s clinical development solutions include clinical trial execution, site management, patient recruitment and regulatory affairs support. IQVIA also delivers real-world evidence and analytics through its expansive health information database, drawing on electronic health records, claims data and patient registries. Its technology platforms, such as the Orchestrated Customer Engagement suite and the E360 commercial analytics tool, enable clients to streamline operations, improve decision making and enhance patient engagement.
Operating in over 100 countries, IQVIA serves pharmaceutical, biotechnology, medical device and diagnostic companies, as well as payers and government health agencies. The firm maintains a network of regional offices and research centers across North America, Europe, Asia Pacific, Latin America and the Middle East. This global footprint allows IQVIA to support multi-jurisdictional clinical trials and to deliver localized insights for diverse healthcare markets.
IQVIA was formed in 2016 through the merger of IMS Health, founded in 1954 as a market intelligence provider, and Quintiles, established in 1982 as a contract research organization. Headquartered in Durham, North Carolina, the company is led by Chairman and Chief Executive Officer Ari Bousbib, who has guided its growth into a leading human data science enterprise. Under his leadership, IQVIA continues to invest in next-generation technologies and strategic partnerships to advance innovation in healthcare.
